Bioson Pharmaceutical Signs MOU with SPC for Active Pharmaceutical Ingredients Business

Biosolution Pharmaceuticals announced on the 5th that it has signed a memorandum of understanding (MOU) with SPC Co., Ltd., a pharmaceutical company specializing in active pharmaceutical ingredients (API), to jointly pursue the API business. This agreement is part of a strategic partnership aimed at strengthening competitiveness in the domestic and international API sectors based on the technologies and infrastructure possessed by both companies.

Jang Buhwan (left), CEO of Vibozone Pharmaceuticals, and Lee Gunho, CEO of SPC, are posing for a commemorative photo after signing a business cooperation agreement. Photo by Vibozone Pharmaceuticals

SPC is a specialized company in the development and manufacturing of APIs, producing key raw materials for over-the-counter drugs such as gastroesophageal reflux disease treatments and cephalosporin antibiotics. In particular, it manufactures high-quality APIs based on Good Manufacturing Practice (GMP) production facilities.

Biosolution Pharmaceuticals plans to expand its scope to the API business, which is a core raw material necessary for finished drug manufacturing, by utilizing SPC’s API production infrastructure and technological capabilities. This is expected to enhance the competitiveness of drug quality and production systems.

Jang Buhwan, CEO of Biosolution Pharmaceuticals, stated, “This collaboration is an important opportunity to secure future growth engines for Biosolution Pharmaceuticals,” adding, “We will do our best to establish a stable drug production system and enhance corporate competitiveness.”